McKeage K, Romanowski B; Drugs 71 (4), 465-8 (Mar 2011) The AS04-adjuvanted human papillomavirus (HPV) 16/18 vaccine (Cervarix®) is a noninfectious recombinant vaccine produced using purified virus-like particles (VLPs) that induce a strong immunogenic response eliciting high levels of anti-L1 VLP antibodies that persist at levels markedly greater than those observed with natural infection. The […]
Read all of this leaflet carefully before you start receiving this vaccine. – Keep this leaflet. You may need to read it again. – If you have any further questions, ask your doctor or pharmacist. – This medicine has been prescribed for you. Do not pass it on to others. – If any of the […]
CONTRAINDICATIONS Severe allergic reactions (e.g., anaphylaxis) to any component of CERVARIX. WARNINGS AND PRECAUTIONS Syncope Because vaccinees may develop syncope, sometimes resulting in falling with injury, observation for 15 minutes after administration is recommended. Syncope, sometimes associated with tonic-clonic movements and other seizure-like activity, has been reported following vaccination with CERVARIX. When syncope is associated […]
Authorisation details Product information Assessment history Read reports here.
Proper Name: Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant Tradename: Cervarix Manufacturer: GlaxoSmithKline Biologicals 16 October 2009, Cervarix® was approved for use in the United States, by the FDA. To examine all available FDA documents pertaining to the approval of this HPV vaccine visit the two FDA links below. Proper Name: Human Papillomavirus […]